Table 2 Multivariate Cox-regression for glioblastoma patients.
From: Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas
Variable | No. | Baseline | EGR1 | EGR3 | |||
|---|---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
(A) All patients | |||||||
Age | 190 | 1.02 (1.01–1.04) | 0.004 | 1.02 (1.01–1.04) | 0.004 | 1.02 (1.01–1.04) | 0.003 |
Post-surgical treatment | |||||||
None | 18 | 1.00 | 1.00 | 1.00 | |||
Stupp | 144 | 0.51 (0.27–0.95) | 0.03 | 0.51 (0.27–0.95) | 0.03 | 0.54 (0.29–1.00) | 0.05 |
Radiation | 28 | 0.95 (0.45–1.97) | 0.88 | 0.95 (0.45–1.98) | 0.89 | 1.06 (0.50–2.27) | 0.16 |
MGMT-methylation status | |||||||
Unmethylated | 71 | 1.00 | 1.00 | 1.00 | |||
Methylated | 94 | 0.51 (0.36–0.74) | 0.001 | 0.54 (0.24–1.20) | 0.13 | 0.51 (0.35–0.74) | 0.001 |
IDH1/2 mutation | |||||||
No | 184 | 1.00 | 1.00 | 1.00 | |||
Yes | 6 | 0.13 (0.03–0.56) | 0.006 | 0.13 (0.03–0.56) | 0.006 | 0.14 (0.03–0.62) | 0.01 |
ECOG Performance status | |||||||
0–1 | 135 | 1.00 | 1.00 | 1.00 | |||
2–4 | 54 | 2.78 (1.81–4.31) | <0.001 | 2.79 (1.81–4.31) | <0.001 | 2.72 (1.76–4.21) | <0.001 |
Gender | |||||||
Female | 82 | 1.00 | 1.00 | 1.00 | |||
Male | 108 | 0.94 (0.67–1.33) | 0.27 | 0.94 (0.67–1.33) | 0.27 | 0.94 (0.66–1.32) | 0.70 |
EGR1 fraction | |||||||
Low | 95 | — | — | 1.00 | — | — | |
High | 95 | — | — | 0.95 (0.43–2.11) | 0.91 | — | — |
EGR3 fraction | |||||||
Low | 95 | — | — | — | — | 1.00 | |
High | 95 | — | — | — | — | 1.26 (0.90–1.77) | 0.18 |
(B) Patients with methylated MGMT-promoter. | |||||||
Age | 94 | 1.04 (1.01–1.06) | 0.001 | 1.04 (1.01–1.06) | 0.001 | 1.04 (1.01–1.06) | 0.001 |
Post-surgical treatment | |||||||
None | 8 | 1.00 | 1.00 | 1.00 | |||
Stupp | 76 | 0.20 (0.07–0.59) | 0.003 | 0.20 (0.07–0.59) | 0.004 | 0.12 (0.04–0.39) | <0.001 |
Radiation | 10 | 0.42 (0.15–1.14) | 0.09 | 0.42 (0.15–1.14) | 0.09 | 0.35 (0.13–0.98) | 0.045 |
IDH1/2 mutation | |||||||
No | 92 | 1.00 | n/a | 1.00 | n/a | 1.00 | n/a |
Yes | 2 | n/a | n/a | n/a | |||
ECOG Performance status | |||||||
0–1 | 66 | 1.00 | 1.00 | 1.00 | |||
2–4 | 28 | 2.71 (1.39–5.29) | 0.003 | 2.71 (1.39–5.29) | 0.003 | 2.22 (1.10–4.45) | 0.03 |
Gender | |||||||
Female | 43 | 1.00 | 1.00 | 1.00 | |||
Male | 51 | 1.07 (0.66–1.75) | 0.77 | 1.07 (0.66–1.75) | 0.77 | 0.99 (0.61–1.61) | 0.96 |
EGR1 fraction | — | — | — | — | |||
Low | 9 | — | — | 1.00 | — | — | |
High | 85 | — | — | 0.99 (0.44–2.22) | 0.99 | — | — |
EGR3 fraction | — | — | — | — | |||
Low | 45 | — | — | — | — | 1.00 | |
High | 49 | — | — | — | — | 1.97 (1.19–3.28) | 0.009 |
(C) Patients with un-methylated MGMT-promoter. | |||||||
Age | 71 | 0.99 (0.97–1.03) | 0.94 | 0.99 (0.97–1.03) | 0.94 | 1.00 (0.97–1.03) | 0.96 |
Post-surgical treatment | |||||||
None | 8 | 1.00 | 1.00 | 1.00 | |||
Stupp | 52 | 1.02 (0.42–2.47) | 0.96 | 1.02 (0.42–2.47) | 0.96 | 1.09 (0.42–2.85) | 0.86 |
Radiation | 11 | 2.08 (0.66–6.57) | 0.21 | 2.08 (0.66–6.57) | 0.21 | 2.24 (0.66–7.67) | 0.19 |
IDH1/2 mutation | |||||||
No | 67 | 1.00 | 0.01 | 1.00 | 0.01 | 1.00 | 0.01 |
Yes | 4 | 0.11 (0.02–0.60) | 0.11 (0.02–0.60) | 0.11 (0.02–0.59) | |||
ECOG Performance status | |||||||
0–1 | 52 | 1.00 | 1.00 | 1.00 | |||
2–4 | 19 | 3.43 (1.66–7.10) | 0.001 | 3.43 (1.66–7.10) | 0.001 | 3.53 (1.67–7.48) | 0.001 |
Gender | |||||||
Female | 25 | 1.00 | 1.00 | 1.00 | |||
Male | 46 | 0.95 (0.54–1.66) | 0.84 | 0.95 (0.54–1.66) | 0.84 | 0.97 (0.54–1.73) | 0.92 |
EGR1 fraction | — | — | — | — | |||
Low | 71 | — | — | 1.00 | — | — | |
High | 0 | — | — | n/a | n/a | — | — |
EGR3 fraction | — | — | — | — | |||
Low | 39 | — | — | — | — | 1.00 | |
High | 32 | — | — | — | — | 1.10 (0.64–1.90) | 0.72 |
